Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

Modern Rheumatology

Volumn 21, Issue 3, 2011, Pages 267-275

  Akashi, Naotsugu ^a,b   Matsumoto, Isao ^a   Tanaka, Yoko ^a   Inoue, Asuka ^a   Yamamoto, Kayo ^a   Umeda, Naoto ^a   Tanaka, Yuki ^a   Hayashi, Taichi ^a   Goto, Daisuke ^a   Ito, Satoshi ^a   Sekiguchi, Kaneo ^b   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

GPI and arthritis; Imatinib; Nilotinib

Indexed keywords

GAMMA INTERFERON; GLUCOSE 6 PHOSPHATE ISOMERASE; IMATINIB; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; NILOTINIB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; IN VITRO STUDY; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; ARTHRITIS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLUCOSE-6-PHOSPHATE ISOMERASE; INTERLEUKIN-17; MALE; MICE; MICE, INBRED DBA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECOMBINANT PROTEINS; SPLEEN;

EID: 79960136098     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0392-5     Document Type: Article

References (26)

1. I Matsumoto A Staub C Benoist D Mathis 1999 Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme Science 286 5445 1732 1735 10576739 10.1126/science.286.5445.1732 1:CAS:528:DyaK1MXnsl2gurg%3D (Pubitemid 129515879)
2. D Schubert B Maier L Morawietz V Krenn T Kamradt 2004 Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice J Immunol 172 4503 4509 15034067 1:CAS:528:DC%2BD2cXitlOqtLg%3D (Pubitemid 38375267)
3. K Iwanami I Matsumoto Y Tanaka-Watanabe A Inoue M Mihara Y Ohsugi, et al. 2008 Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase Arthritis Rheum 58 3 754 763 18311788 10.1002/art.23222 1:CAS:528:DC%2BD1cXjslWqu74%3D (Pubitemid 351364873)
4. I Matsumoto H Zhang T Yasukochi K Iwanami Y Tanaka A Inoue, et al. 2008 Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis Arthritis Res Ther 10 3 R66 18534002 10.1186/ar2437 (Pubitemid 351895459)
5. A Quintás-Cardama H Kantarjian J Cortes 2009 Imatinib and beyond - exploring the full potential of targeted therapy for CML Nat Rev Clin Oncol 6 9 535 543 19652654 10.1038/nrclinonc.2009.112
6. PW Manley P Drueckes G Fendrich P Furet J Liebetanz G Martiny-Baron, et al. 2010 Extended kinase profile and properties of the protein kinase inhibitor nilotinib Biochim Biophys Acta 1804 3 445 453 19922818 1:CAS:528: DC%2BC3cXhs1ynu78%3D
7. RW Kinne R Brauer B Stuhlmuller E Palombo-Kinne GR Burmester 2000 Macrophages in rheumatoid arthritis Arthritis Res 222 189 202 10.1186/ar86 (Pubitemid 32223726)
8. CM Weyand JJ Goronzy 2006 T-cell-targeted therapies in rheumatoid arthritis Nat Clin Pract Rheumatol 2 4 201 210 16932686 10.1038/ncprheum0142 1:CAS:528:DC%2BD28XksFKisr0%3D
9. N Brownlow AE Russell H Saravanapavan M Wiesmann JM Murray PW Manley, et al. 2008 Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis Leukemia 22 3 649 652 17851554 10.1038/sj.leu.2404944 1:CAS:528:DC%2BD1cXjt1Ggu7Y%3D (Pubitemid 351386741)
10. SJ Blake AB Lyons TP Hughes 2009 Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro J Cell Mol Med 13 3 599 601 19374687 10.1111/j.1582-4934.2009.00500-1.x 1:CAS:528:DC%2BD1MXltFSktb8%3D
11. K Cwynarski R Laylor E Macchiarulo J Goldman G Lombardi JV Melo, et al. 2004 Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro Leukemia 18 8 1332 1339 15190258 10.1038/sj.leu.2403401 1:CAS:528:DC%2BD2cXlvVehsr0%3D (Pubitemid 39136740)
12. I Matsumoto DM Lee R Goldbach-Mansky T Sumida CA Hitchon PH Schur, et al. 2003 Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders Arthritis Rheum 48 944 954 12687536 10.1002/art.10898 1:CAS:528: DC%2BD3sXjtlKnsrg%3D (Pubitemid 36418236)
13. RT Paniagua O Sharpe PP Ho SM Chan A Chang JP Higgins, et al. 2006 Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis J Clin Invest 116 10 2633 2642 16981009 1:CAS:528:DC%2BD28XhtVKgu7rI (Pubitemid 44511627)
14. C Cullinane A Natoli Y Hui N Conus S Jackson J Brüggen, et al. 2010 Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model Mol Cancer Ther 9 5 1461 1468 20442311 10.1158/1535-7163.MCT-09- 1181 1:CAS:528:DC%2BC3cXlslektbc%3D
15. RT Paniagua A Chang MM Mariano EA Stein Q Wang TM Lindstrom, et al. 2010 c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis Arthritis Res Ther 12 1 R32 20181277 10.1186/ar2940
16. F Terabe M Kitano M Kawai Y Kuwahara T Hirano J Arimitsu, et al. 2009 Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway Mod Rheumatol 19 5 522 529 19568828 10.1007/s10165-009-0193-x 1:CAS:528: DC%2BD1MXht1Ggtr7K
17. K Koyama K Hatsushika T Ando M Sakuma M Wako R Kato, et al. 2007 Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice Mod Rheumatol 17 4 306 310 17694264 10.1007/s10165-007-0592-9 1:CAS:528:DC%2BD2sXovFSlsLo%3D (Pubitemid 47263822)
18. A Inoue I Matsumoto Y Tanaka K Iwanami A Kanamori N Ochiai D Goto S Ito T Sumida 2009 Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis Arthritis Res Ther 11 4 R118 19660107 10.1186/ar2779
19. K Takatsu 1997 Cytokines involved in B-cell differentiation and their sites of action Proc Soc Exp Biol Med 215 2 121 133 9160040 1:CAS:528: DyaK2sXjtlSqu7o%3D
20. O Dienz SM Eaton JP Bond W Neveu D Moquin R Noubade, et al. 2009 The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells J Exp Med 206 1 69 78 19139170 10.1084/jem.20081571 1:CAS:528:DC%2BD1MXhtVOhtbk%3D
21. E Weisberg PW Manley W Breitenstein J Brüggen SW Cowan-Jacob A Ray, et al. 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2 129 141 15710326 10.1016/j.ccr.2005.01.007 1:CAS:528:DC%2BD2MXitFygu7o%3D (Pubitemid 40248339)
22. J Salih J Hilpert T Placke F Grünebach A Steinle HR Salih, et al. 2010 The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity Int J Cancer 127 9 2119 2128 20143399 10.1002/ijc.25233 1:CAS:528:DC%2BC3cXhtFSisrnK
23. MW Karaman S Herrgard DK Treiber P Gallant CE Atteridge BT Campbell, et al. 2008 A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 1 127 132 18183025 10.1038/nbt1358 1:CAS:528:DC%2BD1cXisFGlsQ%3D%3D
24. K Miyachi A Ihara RW Hankins R Murai S Maehiro H Miyashita 2003 Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia Clin Rheumatol 22 4-5 329 332 14576993 10.1007/s10067-003-0716-3 1:STN:280:DC%2BD3svpvVOkuw%3D%3D (Pubitemid 37483630)
25. KK Eklund H Joensuu 2003 Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases Ann Med 35 5 362 367 12952023 10.1080/07853890310001339 1:CAS:528:DC%2BD3sXmtVeltrk%3D (Pubitemid 37013677)
26. H Kameda 2009 Imatinib Nihon Rinsho Meneki Gakkai Kaishi 32 2 77 84 19404005 1:CAS:528:DC%2BC3cXhsFalur0%3D